Novartis Trial Setback Pressures Cholesterol Pipeline at Amgen and Eli Lilly

According to reporting from Yahoo Finance, the clinical failure of Novartis' drug pelacarsen has cast a shadow over competing cardiovascular programs. Both Amgen and Eli Lilly are currently developing similar treatments focused on reducing lipoprotein(a), but they must now prove

According to reporting from Yahoo Finance, the clinical failure of Novartis' drug pelacarsen has cast a shadow over competing cardiovascular programs. Both Amgen and Eli Lilly are currently developing similar treatments focused on reducing lipoprotein(a), but they must now prove